Sign In
Buy BLCO
Bausch + Lomb Earnings Calls
| Release date | Oct 29, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.180 |
| EPS Surprise | 12.50% |
| Revenue estimate | 1.278B |
| Revenue actual | 1.281B |
| Revenue Surprise | 0.249% |
| Release date | Jul 30, 2025 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0700 |
| EPS Surprise | 16.67% |
| Revenue estimate | 1.274B |
| Revenue actual | 1.278B |
| Revenue Surprise | 0.305% |
| Release date | Apr 30, 2025 |
| EPS estimate | $0.0300 |
| EPS actual | -$0.0700 |
| EPS Surprise | -333.33% |
| Revenue estimate | 1.253B |
| Revenue actual | 1.133B |
| Revenue Surprise | -9.58% |
| Release date | Feb 19, 2025 |
| EPS estimate | $0.240 |
| EPS actual | $0.250 |
| EPS Surprise | 4.17% |
| Revenue estimate | 1.151B |
| Revenue actual | 1.28B |
| Revenue Surprise | 11.23% |
Last 4 Quarters for Bausch + Lomb
Below you can see how BLCO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 19, 2025 |
| Price on release | $16.30 |
| EPS estimate | $0.240 |
| EPS actual | $0.250 |
| EPS surprise | 4.17% |
| Date | Price |
|---|---|
| Feb 12, 2025 | $16.44 |
| Feb 13, 2025 | $16.64 |
| Feb 14, 2025 | $16.41 |
| Feb 18, 2025 | $16.35 |
| Feb 19, 2025 | $16.30 |
| Feb 20, 2025 | $15.89 |
| Feb 21, 2025 | $15.75 |
| Feb 24, 2025 | $15.81 |
| Feb 25, 2025 | $15.97 |
| 4 days before | -0.85% |
| 4 days after | -2.02% |
| On release day | -2.52% |
| Change in period | -2.86% |
| Release date | Apr 30, 2025 |
| Price on release | $11.56 |
| EPS estimate | $0.0300 |
| EPS actual | -$0.0700 |
| EPS surprise | -333.33% |
| Date | Price |
|---|---|
| Apr 24, 2025 | $13.89 |
| Apr 25, 2025 | $13.73 |
| Apr 28, 2025 | $13.66 |
| Apr 29, 2025 | $13.72 |
| Apr 30, 2025 | $11.56 |
| May 01, 2025 | $11.59 |
| May 02, 2025 | $11.50 |
| May 05, 2025 | $11.37 |
| May 06, 2025 | $10.90 |
| 4 days before | -16.77% |
| 4 days after | -5.71% |
| On release day | 0.260% |
| Change in period | -21.53% |
| Release date | Jul 30, 2025 |
| Price on release | $13.71 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0700 |
| EPS surprise | 16.67% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $13.97 |
| Jul 25, 2025 | $14.32 |
| Jul 28, 2025 | $14.44 |
| Jul 29, 2025 | $14.65 |
| Jul 30, 2025 | $13.71 |
| Jul 31, 2025 | $13.63 |
| Aug 01, 2025 | $13.50 |
| Aug 04, 2025 | $13.72 |
| Aug 05, 2025 | $14.44 |
| 4 days before | -1.86% |
| 4 days after | 5.32% |
| On release day | -0.584% |
| Change in period | 3.36% |
| Release date | Oct 29, 2025 |
| Price on release | $15.47 |
| EPS estimate | $0.160 |
| EPS actual | $0.180 |
| EPS surprise | 12.50% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $15.78 |
| Oct 24, 2025 | $15.52 |
| Oct 27, 2025 | $15.37 |
| Oct 28, 2025 | $15.20 |
| Oct 29, 2025 | $15.47 |
| Oct 30, 2025 | $15.14 |
| Oct 31, 2025 | $14.94 |
| Nov 03, 2025 | $15.25 |
| Nov 04, 2025 | $15.00 |
| 4 days before | -1.96% |
| 4 days after | -3.04% |
| On release day | -2.13% |
| Change in period | -4.94% |
Bausch + Lomb Earnings Call Transcript Summary of Q3 2025
Bausch + Lomb reported a strong Q3 2025 driven by broad-based growth across Vision Care, Surgical and Pharmaceuticals. Total revenue was $1.281 billion, up 6% year-over-year on a constant currency basis. Key drivers: Miebo (Q3 revenue $84M, TRx +110% YoY) and Xiidra (Q3 revenue $87M, TRx +8%), continuation of momentum in the Daily SiHy contact lens franchise (+24% YoY), and strong consumer brands including Blink (+36%) and Artelac (+18%). Surgical is recovering from the enVista recall — enVista sales in Q3 reached 82% of pre-recall Q1 levels and Envy reached 91%, with September Envy monthly sales surpassing Q1 averages. Adjusted EBITDA (ex-acquired IPR&D) was $243M (+7% YoY) and adjusted EBITDA margin (ex-acquired IPR&D) improved sequentially by ~400 bps to 19%. Adjusted cash flow from operations was $161M and adjusted free cash flow was $87M. Management maintained full-year revenue guidance of $5.05B–$5.15B (≈5–7% constant currency growth) and raised the lower end of adjusted EBITDA guidance to $870M–$910M. They reiterated continued investment in R&D (~7.5% of revenue expected) while emphasizing a new fourth strategic pillar — financial excellence (Vision '27) — aimed at disciplined allocation, margin expansion and improved cash conversion. Management also said tariffs remain a fluid risk but they currently expect to offset tariff impacts in 2025. Investor Day is scheduled for November 13 to provide a detailed 3-year plan and R&D pipeline roadmap.
